View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 18, 2022

Kinnate doses first subject in Phase I trial of FGFR inhibitor

The trial will assess the safety, tolerability, pharmacokinetics, and initial efficacy of KIN-3248 in adults.

Kinnate Biopharma has dosed the first subject in Phase I KN-4802 clinical trial of its Fibroblast Growth Factor Receptor (FGFR) product candidate, KIN-3248.

An irreversible, small molecule pan-FGFR inhibitor, KIN-3248 is being developed to treat intrahepatic cholangiocarcinoma (ICC), urothelial carcinoma (UC) and various other solid tumours.

It can potentially act on both primary FGFR2 and FGFR3 oncogenic alterations and those claimed to induce acquired resistance to existing FGFR-targeted treatments, including gatekeeper, molecular brake and activation loop mutations seen in tumours such as ICC and UC.

The open-label, multicentre, two-part trial will assess the safety, tolerability, pharmacokinetics (PK), and initial efficacy of KIN-3248 in adult subjects.

It will enrol a total of 120 subjects with advanced cancers with FGFR2 and/or FGFR3 gene alterations.

The Part A or dose-escalation segment of the trial will detect the recommended dose and dosing schedule of the company’s FGFR inhibitor for further analysis in individuals with FGFR2 and/or FGFR3 gene alteration-driven tumours.

In the dose-expansion phase or Part B of the trial, the safety and efficacy of the KIN-3248 at the recommended dose and schedule will be analysed in FGFR inhibitor-naïve and -pre-treated subjects with FGFR2 and/or FGFR3 gene alteration-driven cancers.

Kinnate chief medical officer Richard Williams said: “With the dosing of the first patient in our Phase I trial of KIN-3248, we are excited to further advance the development of this next-generation therapy which we believe is unique among FGFR inhibitors and has the potential to offer a new targeted therapy option for cancer patients with FGFR-altered tumours.

“We are grateful for the contribution of all the participants in this multicentre trial and for the support of our clinical collaborators at each trial site.”

KIN-3248 was found to possess inhibitory activity across various clinically significant mutations that induce primary disease and acquired resistance to other FGFR inhibitors, in preclinical studies.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU